Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 667

1.

Disease activity assessment in patients with psoriatic arthritis.

Kerschbaumer A, Smolen JS, Aletaha D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):401-414. doi: 10.1016/j.berh.2018.08.004. Epub 2018 Oct 11. Review.

PMID:
31171311
2.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23.

PMID:
31130260
3.

Greetings from the editor.

Smolen JS.

Ann Rheum Dis. 2019 Jun;78(6):715. doi: 10.1136/annrheumdis-2019-215621. No abstract available.

PMID:
31088798
4.

Multimodal [18 F]FDG PET/CT is a direct readout for inflammatory bone repair: a longitudinal study in TNFα transgenic mice.

Hayer S, Zeilinger M, Weiss V, Dumanic M, Seibt M, Niederreiter B, Shvets T, Pichler F, Wadsak W, Podesser BK, Helbich TH, Hacker M, Smolen JS, Redlich K, Mitterhauser M.

J Bone Miner Res. 2019 May 7. doi: 10.1002/jbmr.3748. [Epub ahead of print]

PMID:
31063606
5.

Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study.

Leiss H, Hucke M, Bécède M, Machold-Fabrizii V, Smolen JS, Machold KP.

Sci Rep. 2019 Apr 10;9(1):5867. doi: 10.1038/s41598-019-42387-4.

6.

Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate-treated rheumatoid arthritis patients in OPTIMA.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Apr 9. [Epub ahead of print]

PMID:
30963994
7.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
8.

Risk profiling for a refractory course of rheumatoid arthritis.

Bécède M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D.

Semin Arthritis Rheum. 2019 Feb 8. pii: S0049-0172(18)30553-5. doi: 10.1016/j.semarthrit.2019.02.004. [Epub ahead of print]

9.

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.

Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y.

Mod Rheumatol. 2019 Feb 20:1-8. doi: 10.1080/14397595.2019.1583711. [Epub ahead of print]

PMID:
30784354
10.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
11.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, Nurwakagari P, Weinman J.

RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019.

12.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
13.

I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis.

Mosor E, Stoffer-Marx M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, Skingle D, Dobrin M, Schett G, Englbrecht M, Smolen JS, Kjeken I, Hueber AJ, Stamm TA.

Arthritis Care Res (Hoboken). 2019 Feb 2. doi: 10.1002/acr.23841. [Epub ahead of print]

PMID:
30710453
14.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

PMID:
30692164
15.

FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes.

Brandstetter B, Dalwigk K, Platzer A, Niederreiter B, Kartnig F, Fischer A, Vladimer GI, Byrne RA, Sevelda F, Holinka J, Pap T, Steiner G, Superti-Furga G, Smolen JS, Kiener HP, Karonitsch T.

Lab Invest. 2019 May;99(5):648-658. doi: 10.1038/s41374-018-0184-7. Epub 2019 Jan 24.

PMID:
30679758
16.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
17.

Greetings from the editor 2019.

Smolen JS.

Ann Rheum Dis. 2019 Jan;78(1):1-2. doi: 10.1136/annrheumdis-2018-214822. No abstract available.

PMID:
30563867
18.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2018 Dec 15. pii: jrheum.180478. doi: 10.3899/jrheum.180478. [Epub ahead of print]

PMID:
30554156
19.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

20.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L.

Ann Rheum Dis. 2019 Feb;78(2):201-208. doi: 10.1136/annrheumdis-2018-214140. Epub 2018 Nov 15.

PMID:
30442648
21.

Functional consultation and exercises improve grip strength in osteoarthritis of the hand - a randomised controlled trial.

Stoffer-Marx MA, Klinger M, Luschin S, Meriaux-Kratochvila S, Zettel-Tomenendal M, Nell-Duxneuner V, Zwerina J, Kjeken I, Hackl M, Öhlinger S, Woolf A, Redlich K, Smolen JS, Stamm TA.

Arthritis Res Ther. 2018 Nov 9;20(1):253. doi: 10.1186/s13075-018-1747-0.

22.

I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis.

Ritschl V, Lackner A, Boström C, Mosor E, Lehner M, Omara M, Ramos R, Studenic P, Smolen JS, Stamm TA.

Arthritis Res Ther. 2018 Oct 19;20(1):234. doi: 10.1186/s13075-018-1732-7.

23.

Diagnosis and Management of Rheumatoid Arthritis: A Review.

Aletaha D, Smolen JS.

JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Review.

PMID:
30285183
24.

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, Kroon FPB, Punzi L, Smolen JS, Vander Cruyssen B, Wolterbeek R, Verbruggen G, Wittoek R.

Ann Rheum Dis. 2018 Dec;77(12):1757-1764. doi: 10.1136/annrheumdis-2018-213202. Epub 2018 Oct 3.

PMID:
30282670
25.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
26.

Adverse Events and Resource Use Before and After Treat to Target in Rheumatoid Arthritis:A Post-Hoc Analysis of a Randomized Controlled Trial.

Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B.

Arthritis Care Res (Hoboken). 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]

PMID:
30221841
27.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL.

J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.

28.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS.

Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.

29.

2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJ, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L.

Ann Rheum Dis. 2019 Jan;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.

PMID:
30154087
30.

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.

Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A.

Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3.

31.

Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial.

Zak A, Corrigan C, Yu Z, Bitton A, Fraenkel L, Harrold L, Smolen JS, Solomon DH.

Rheumatology (Oxford). 2018 Nov 1;57(11):1933-1937. doi: 10.1093/rheumatology/key179.

PMID:
29982720
32.

Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H.

Vaccine. 2018 Aug 6;36(32 Pt B):4875-4879. doi: 10.1016/j.vaccine.2018.06.065. Epub 2018 Jul 3.

PMID:
29980390
33.

Non-classical monocytes as mediators of tissue destruction in arthritis.

Puchner A, Saferding V, Bonelli M, Mikami Y, Hofmann M, Brunner JS, Caldera M, Goncalves-Alves E, Binder NB, Fischer A, Simader E, Steiner CW, Leiss H, Hayer S, Niederreiter B, Karonitsch T, Koenders MI, Podesser BK, O'Shea JJ, Menche J, Smolen JS, Redlich K, Blüml S.

Ann Rheum Dis. 2018 Oct;77(10):1490-1497. doi: 10.1136/annrheumdis-2018-213250. Epub 2018 Jun 29.

34.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

35.

mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation.

Karonitsch T, Kandasamy RK, Kartnig F, Herdy B, Dalwigk K, Niederreiter B, Holinka J, Sevelda F, Windhager R, Bilban M, Weichhart T, Säemann M, Pap T, Steiner G, Smolen JS, Kiener HP, Superti-Furga G.

Cell Rep. 2018 May 15;23(7):2157-2167. doi: 10.1016/j.celrep.2018.04.044.

36.

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.

Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS.

Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7. Epub 2018 May 14.

37.

Greetings from the editor.

Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):789. doi: 10.1136/annrheumdis-2018-213599. No abstract available.

PMID:
29748337
38.

To DAPSA or not to DAPSA? That is not the question.

Schoels MM, Smolen JS, Aletaha D.

Ann Rheum Dis. 2019 Jul;78(7):e61. doi: 10.1136/annrheumdis-2018-213548. Epub 2018 May 5. No abstract available.

PMID:
29730635
39.

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.

Jansen DTSL, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE, Ye J, Toes REM, Huizinga TWJ.

RMD Open. 2018 Mar 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564. eCollection 2018.

40.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
41.

Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.

Britsemmer K, van Schaardenburg D, Boers M, De Cock D, Verschueren P, Radner H, Smolen JS, van Tuyl LHD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):362-370. Epub 2018 Feb 26.

PMID:
29533752
42.

Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.

Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D.

Rheumatology (Oxford). 2018 Jun 1;57(6):969-976. doi: 10.1093/rheumatology/key004.

PMID:
29481661
43.

Tofacitinib for Psoriatic Arthritis.

Aletaha D, Kerschbaumer A, Smolen JS.

N Engl J Med. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189. No abstract available.

PMID:
29469555
44.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Review.

45.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
46.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

47.

Advances in targeted therapies 2017.

Breedveld FC, Kalden JR, Smolen JS.

Clin Immunol. 2018 Jan;186:1-2. doi: 10.1016/j.clim.2018.01.007. Epub 2018 Jan 31. No abstract available.

PMID:
29378299
49.

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.

Solomon DH, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina E.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1551-1556. doi: 10.1002/acr.23508.

PMID:
29316341
50.

The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands.

Hifinger M, Ramiro S, Putrik P, van Eijk-Hustings Y, Woolf A, Smolen JS, Stoffer-Marx M, Uhlig T, Moe RH, Saritas M, Janson M, van der Helm-van Mil A, van de Laar M, Vonkeman H, de Wit M, Boonen A.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):275-283. Epub 2017 Dec 15.

PMID:
29303700

Supplemental Content

Loading ...
Support Center